Clinical Trials Logo
  1. Home
  2. Endocarditis, Bacterial
  3. NCT03306225
  4. Details
NCT03306225 Clinical Trial

Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients

Endocarditis, Bacterial Clinical Trial

Official title:
Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03306225
Other study ID # ENDOSTREPTO
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 8, 2016
Est. completion date December 31, 2019

Study information
Verified date January 2020
Source Groupe Hospitalier Paris Saint Joseph
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The infectious endocarditis is a grave infection the incidence of which is at present esteemed at 30-100 episodes by million inhabitants a year.

This infection is marked with a heavy morbi-mortality.Preliminary studies seem to show an abnormally high death rate at the patients presenting an infectious endocarditis to streptococci with an inhibitive minimal concentration raised to the amoxicilline. The aim of the study is to describe the epidemiology and the clinical presentations of the patients presenting an endocarditis to streptococci

Recruitment information / eligibility
Status Completed
Enrollment 414
Est. completion date December 31, 2019
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age > 18 years

- endocartitis with steptococci with Duke's criteria

Exclusion Criteria:

- age < 18 years

- suspiscious endocarditis without Duke's criteria

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France

Sponsors (1)
Lead Sponsor Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluation of factors associated to the mortality in the patients presenting an endocarditis to streptococci. an average of one year
See also
  Status Clinical Trial Phase
Terminated NCT00401960 - Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. Phase 4
Terminated NCT00695903 - Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia Phase 2
Recruiting NCT05644990 - T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
Recruiting NCT04840225 - Anemia in Patients With Endocarditis
Completed NCT00524212 - How to Improve Diagnosis in Infective Endocarditis N/A
Completed NCT03048643 - Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis N/A
Completed NCT00144885 - IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis N/A
Active, not recruiting NCT05522764 - Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Terminated NCT04222257 - Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis Phase 4
Not yet recruiting NCT05152225 - Neurological Complication of Infective Endocarditis: A Prospective Multi-site Cohort Study
Not yet recruiting NCT05613933 - Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis N/A
Recruiting NCT02979951 - Fosfomycin i.v. for Treatment of Severely Infected Patients
Recruiting NCT06250985 - New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System Phase 3